ETON
Eton Pharmaceuticals, Inc.
$50.00
-0.04%
2026-10-23
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Key Fundamentals
P/E Ratio
147.90
Forward P/E
22.36
EPS (TTM)
$0.39
ROE
36.0%
Revenue Growth (YoY)
98.6%
Profit Margin
12.0%
Debt/Equity
62.73
Price/Book
35.02
Beta
0.90
Market Cap
$1.65B
Avg Volume (10D)
474K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$66.37
60D Low
$40.61
Avg Volume
579K
Latest Close
$50.00
Get breakout alerts for ETON
Sign up for Breakout Scanner to receive daily notifications when ETON triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Eton Pharmaceuticals, Inc. (ETON) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ETON daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ETON operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.